Pet BAFF/APRIL Therapeutic Antibody Development

The development of therapeutic antibodies targeting BAFF (B-cell activating factor) and APRIL (A Proliferation-Inducing Ligand) is an emerging and promising direction in veterinary biotherapeutics. Creative Biolabs is dedicated to advancing next-generation biologics for companion animals by providing comprehensive research and development services for canine and feline BAFF/APRIL-targeted antibody therapeutics. Our expertise spans antibody discovery, optimization, and preclinical evaluation, helping clients translate innovative concepts into veterinary therapeutics designed to address autoimmune and inflammatory diseases in pets.

Platforms in Therapeutic Antibody Discovery

Creative Biolabs offers an integrated suite of discovery platforms to accelerate the generation of pet-specific therapeutic antibodies against BAFF and APRIL.

• Phage Display: Our proprietary phage display libraries are designed using canine and feline antibody repertoires, ensuring species-specific binding and reduced immunogenicity. This platform allows efficient screening of high-affinity antibody candidates against BAFF and APRIL, streamlining the transition from discovery to functional validation.
• Single-B Cell Sorting: This platform enables the isolation of naturally occurring, high-affinity antibodies from immunized animals or patient-derived samples. We use this technology to identify murine-derived antibody leads suitable for engineering into canine or feline IgG frameworks for downstream optimization.
• Hybridoma Technology: Our hybridoma-based approach supports the generation of monoclonal antibodies for early-stage functional characterization and subsequent engineering into recombinant canine or feline antibody backbones.

Comprehensive Antibody Development Services

Our service portfolio covers every stage of antibody development, ensuring your BAFF/APRIL antibody projects advance efficiently.

Antibody Characterization

We perform affinity, specificity, and epitope mapping studies to ensure target engagement accuracy and predict in vivo performance.

Antibody Engineering

Using state-of-the-art molecular tools, we caninize or felinize species-adapt antibodies, enhance Fc function, and optimize pharmacokinetics for canine or feline applications.

Preclinical Evaluation

Our integrated in vitro and in vivo studies evaluate antibody safety, immunogenicity, and therapeutic efficacy using species-relevant models.

Antibody Development

From early R&D through scale-up production, Creative Biolabs provides end-to-end development services that prepare antibodies for further translation.

Discover How We Can Help - Request a Consultation

Why Focus on BAFF / APRIL?

BAFF and APRIL are crucial members of the TNF ligand family that regulate B-cell survival, maturation, and antibody production. Aberrant BAFF/APRIL signaling has been implicated in autoimmune diseases such as systemic lupus erythematosus (SLE)-like syndromes, immune-mediated hemolytic anemia, and chronic inflammatory conditions observed in dogs and cats. Therapeutic antibodies that neutralize BAFF or block BAFF/APRIL receptor interactions may restore immune homeostasis and reduce autoreactive B-cell activity, providing targeted immunomodulatory therapy for veterinary medicine. Such antibodies hold significant potential for treating canine autoimmune disorders and feline chronic inflammatory diseases.

Mechanism of Action

Antibodies targeting BAFF or APRIL act by inhibiting their interaction with receptors such as BAFF-R, TACI, and BCMA on B cells. This blockade disrupts pro-survival signaling pathways that promote B-cell differentiation and immunoglobulin production. By reducing BAFF/APRIL-mediated B-cell activation, these therapeutic antibodies downregulate pathogenic antibody production and attenuate autoimmune responses. In canine or feline models, this mechanism offers a highly specific approach to reestablish immune balance without broad immunosuppression, minimizing systemic side effects.

Fig 1. Gene expression of APRIL/BAFF in the spleens of dogs.¹

Our Advantages

• Species-Specific Expertise: Dedicated platforms for canine and feline antibody discovery ensure physiological compatibility and minimize immunogenicity.
• Comprehensive Development Pipeline: From antigen design to in vivo efficacy testing, we provide fully integrated services under one roof.
• Cutting-Edge Immunology Knowledge: Our scientists possess deep expertise in autoimmune mechanisms and veterinary immunotherapy innovation.
• Collaborative Project Design: We tailor research strategies to your therapeutic goals, ensuring transparency, flexibility, and scientific rigor.

Partner with Creative Biolabs

BAFF and APRIL are promising immunotherapeutic targets for controlling autoimmune and chronic inflammatory diseases in companion animals. Partnering with Creative Biolabs gives you access to advanced discovery technologies, in-depth immunological insight, and a multidisciplinary team committed to translating scientific ideas into practical veterinary therapeutics. Whether you are in the early conceptual stage or ready for preclinical evaluation, we invite you to contact us today to begin your pet BAFF/APRIL therapeutic antibody development journey with Creative Biolabs.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Silva-O'Hare, Joselli, et al. "Disruption of splenic lymphoid tissue and plasmacytosis in canine visceral leishmaniasis: changes in homing and survival of plasma cells." PLoS One 11.5 (2016): e0156733. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1371/journal.pone.0156733